A systematic review investigating the safety and efficacy of intravenous iron in people with ND-CKD who are iron deficient but not anaemic
Clicks: 2
ID: 316394
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #126 of 129 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ABSTRACT Background The role of intravenous (IV) iron in non-dialysis-dependent chronic kidney disease (ND-CKD) without anaemia remains uncertain. Iron deficiency (ID) in CKD is common and associated with impaired mitochondrial function, fatigue, cognitive decline, and restless legs syndrome (RLS), even when haemoglobin (Hb) levels are normalised. ID is linked to cardiovascular (CV) outcomes and increased hospitalisation risk. Guidelines are inconsistent, and the evidence base is limited. Methods Databases were searched for RCTs and cohort studies involving adults with ND-CKD (eGFR < 60) receiving IV iron compared with oral iron, placebo or no treatment. Primary outcome was change in iron indices. Secondary outcomes: CV events, infections, physical function, symptoms, cognition and quality of life (QoL). Results Six studies met the inclusion criteria. In pooled analyses restricted to randomised controlled trials, IV iron significantly improved TSAT (MD + 7.48%, 95% CI 5.64 to 9.32; P < 0.001; I² = 0.0%) and ferritin (MD + 208.83 ng/mL, 95% CI 128.39 to 289.26; P = 0.004; I² = 75.9%). IV iron was associated with a numerically greater increase in haemoglobin, although this did not reach statistical significance (MD + 5.33 g/L, 95% CI − 1.18 to 11.84; P = 0.080; I² = 57.4%). No significant effect was observed on 6-minute walk test distance (MD + 23.99 m, 95% CI − 77.44 to 125.41; P = 0.506; I² = 83.0%). Quality-of-life outcomes showed no significant difference in the primary SMD meta-analysis (SMD − 0.23, 95% CI − 1.44 to 0.98; P = 0.587; I² = 83.2%). Adverse events, cardiovascular outcomes and infections were sparsely reported, with no consistent safety signal identified. Conclusions IV iron improves biochemical markers of iron deficiency in ND-CKD without anaemia, with no clear signal of harm. However, evidence does not demonstrate measurable improvements in physical function or QoL.
| Reference Key |
openalex_W7163875175
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sebastian Spencer, M Skidmore, Rosa Maeve McGing, Sunil Bhandari |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag172
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.